Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Myeloid cell NADPH oxidase isoform 2 (NOX2) generates ROS, and recent research indicates that it is a targetable immune checkpoint in cancer. Here, Anna Martner, PhD, of the University of Gothenburg, Gothenburg, Sweden, discusses her group’s recent research into NOX2 inhibitors in KRAS-induced murine models of myeloproliferative disease.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.